The utility of biomarker risk prediction score in patients with chronic heart failure

Berezin, Alexander Е.; Kremzer, Alexander A.; Martovitskaya, Yulia V.; Berezina, Tatyana A.; Samura, Tatyana A

doi:10.1186/s40885-016-0041-1

Cited by 68 publications

(59 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, there are data clarifying that even asymptomatic hyperuricemia associated strongly with long-term survival of CVD patients and individuals with chronic kidney disease throughout predialysis period and whose who undergoing hemodialysis procedures. In the Rotterdam Study high quartiles of normal rages of SUA and mild increased SUA level were more closely related to early-phase mechanisms of insulin resistance and diabetes mellitus rather than CV complications due to target organ damage progression [8]. Thus, predictive value of SUA in different patients at risk of HF is controversial and requires to be elucidated.…”

Section: Short Communicationmentioning

confidence: 99%

“…Whether SUA could be an independent predictor of HF development is not fully clear. Recent clinical studies and some meta-analysis have shown that elevated SUA levels were associated with an increased risk of incident HF, observed in majority of patients with established chronic HF and relate to adverse clinical outcomes in HF [8][9][10][11]. However, the impact of uric acid on all-cause mortality and HF-related death was…”

Section: Short Communicationmentioning

confidence: 99%

See 1 more Smart Citation

Serum uric acid as a metabolic regulator of endothelial function in heart failure

Berezin¹

2017

Arch Clin Hypertens

View full text Add to dashboard Cite

Citation: Berezin AE (2017) Serum uric acid as a metabolic regulator of endothelial function in heart failure. Arch Clin Hypertens 3(1): 027-029. DOI: http://dx.doi.org/10.17352/ach.000016 AbstractThe development of heart failure (HF) associated with elevated level of serum uric acid (SUA). Additionally, the majority of individuals with traditional cardiovascular risk factors contributing in HF risk exhibited increased levels of SUA. Although SUA lowering drugs are widely used in patients with symptomatic hyperuricemia and gout beyond their etiologies, there is no agreement of SUA below target level 6.0 mg/dL in asymptomatic individuals with kidney injury and CV disease and data of ones in heart failure (HF) are suffi ciently controversial. First SUA plays an important role in inducing oxidative stress, infl ammation, neurohumoral activation, and endothelial dysfunction. Secondary, SUA may act as antioxidant contributing in restoring of vascular function. Moreover, SUA is able to epigenetically regulate a survival of endothelial precursors, mediate their mobbing and differentiation, as well as coordinate a turn-over effect of metabolic memory phenomenon into repair capability of cell precursors. However, elevated SUA level was found a predictor of adverse clinical outcomes of HF. The short communication is depicted the importance of new clinical data to confi rm the emerging reparative ability of SUA in HF and its role as promising target for treatment in cardiac failure. Short Communication Serum uric acid as a metabolic regulator of endothelial function in heart failureAlexander E Berezin* Short CommunicationThere is a large body of evidence regarding the role of serum uric acid (SUA) in pathogenesis of cardiovascular diseases (CVD) including heart failure (HF). Although SUA levels above the current international reference limit equal 6.0 mg/dL are highly prevalent in chronic kidney disease (CKD), hyperuricemia strongly associates with in-hospital CV mortality independently from CKD etiology and renal function in individuals admitted to the hospital due to several causes, i.e. acute myocardial infarction, stroke, hypertensive emergencies, acute / chronic heart failure, arrhythmia, shock and sepsis.In contrast, hypouricemia did not associate with increased mortality rate in patient populations with established CVD [1]. In HF an elevated SUA level was found due to several mechanisms including an increased activity of xanthine oxidase (XO), which is a key enzyme in uric acid synthesis and is under control of infl ammatory cytokines / chemokines, some growth factors, and intermediates (blood glucose). Whether SUA could be an independent predictor of HF development is not fully clear. Recent clinical studies and some meta-analysis have shown that elevated SUA levels were associated with an increased risk of incident HF, observed in majority of patients with established chronic HF and relate to adverse clinical outcomes in HF [8][9][10][11]. However, the impact of uric acid on all-cause mortality and HF-related dea...

show abstract

Section: Short Communicationmentioning

confidence: 99%

Section: Short Communicationmentioning

confidence: 99%

Serum uric acid as a metabolic regulator of endothelial function in heart failure

Berezin¹

2017

Arch Clin Hypertens

View full text Add to dashboard Cite

show abstract

“…Interestingly, there was an association between number of non-classical phenotype EPCs and diabetes mellitus, highly sensitive C-reactive protein, and Agatston score index , whereas CD45-CD34+ EPCs' number did not exhibit similar relations [26]. Moreover, incorporation of number of CD14+CD309+Tie2+ EPCs as a predictive biomarker into biomarker risk score for cumulative CV events in heart failure patients may sufficiently improve sensitivity, specificity, reliability and final discriminative value of the scale [27]. Yang et al [28] reported that count of circulating EPCs with immune phenotype CD34-/CD133+/KDR+ (VEGFR+) may exhibit osteogenic potential and strong correlates with coronary atherosclerosis at the early stage.…”

mentioning

confidence: 99%

Could be Used an Immune Phenotypes of Circulating Endothelial Progenitor Cells as a Biomarker of Cardiovascular Disease?

2017

ARC Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…In contrast, Bondar et al, (2014) [28] have guessed that the gene expression profiling might be useful rather for risk prediction in HF than for choosing HF treatment regime. Thus, the clinical implementation of the HF therapy based on genes scoring remains uncertain and requires more evaluation in the future [29].…”

Section: Introductionmentioning

confidence: 99%

Genetic Predictive Scores in Heart Failure: Possibilities and Expectations

Berezin¹

2016

J Data Mining Genomics Proteomics

View full text Add to dashboard Cite

Heart failure (HF) remains a major health problem worldwide. Currently used HF risk prediction scores based on clinical findings, echocardiography features, biomarkers cannot propose an individualized approach to risk stratification, whereas there is variability in predictive value of different scores amongst patients with various HF phenotypes. The editorial commentary is devoted the role of the genetic risk prediction scores in the predisposition of HF development and assay in the HF medical care response. The brand new risk scores reflecting variabilities in genetic and epigenetic features in HF development are discussed also. Journal of

show abstract

The utility of biomarker risk prediction score in patients with chronic heart failure

Cited by 68 publications

References 37 publications

Serum uric acid as a metabolic regulator of endothelial function in heart failure

Serum uric acid as a metabolic regulator of endothelial function in heart failure

Could be Used an Immune Phenotypes of Circulating Endothelial Progenitor Cells as a Biomarker of Cardiovascular Disease?

Genetic Predictive Scores in Heart Failure: Possibilities and Expectations

Contact Info

Product

Resources

About